Corcept Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $182,546 | $163,796 | $146,808 | $135,405 |
Gross Profit | 179,679 | 161,272 | 144,273 | 133,528 |
EBITDA | 46,598 | 35,592 | 29,620 | 32,241 |
EBIT | 46,099 | 35,335 | 29,500 | 31,669 |
Net Income | 46,690 | 35,488 | 27,762 | 31,355 |
Net Change In Cash | 182,546 | 163,796 | 146,808 | 135,405 |
Free Cash Flow | 72,194 | 40,766 | 23,756 | 5,887 |
Cash | 137,289 | 128,588 | 149,750 | 135,551 |
Basic Shares | 113,723 | 111,244 | 109,915 | 110,886 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $482,375 | $401,858 | $365,978 | $353,874 |
Gross Profit | 475,894 | 396,473 | 360,697 | 348,292 |
EBITDA | 108,324 | 115,603 | 127,544 | 130,439 |
EBIT | 107,282 | 112,634 | 124,477 | 128,202 |
Net Income | 106,140 | 101,418 | 112,512 | 106,011 |
Net Change In Cash | 482,375 | 401,858 | 365,978 | 353,874 |
Cost of Revenue | 1,427 | 44,921 | ||
Free Cash Flow | 126,900 | 119,910 | 167,423 | 150,732 |
Cash | 135,551 | 436,619 | 335,812 | 476,892 |
Basic Shares | 111,742 | 115,966 | 125,963 | 124,194 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.41 |
2024-06-30 | $0.32 |
2024-03-31 | $0.25 |
2023-12-31 | $0.28 |
